Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Satralizumab
Related studies linked through entity extraction aliases.
HANDLE-a Real World Study on Satralizumab in NMOSD
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Status
- RECRUITING
- Phase
- PHASE3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Status
- RECRUITING
- Phase
- PHASE3
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
- Status
- COMPLETED
- Phase
- PHASE3